Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERLINK-1: Monalizumab + Cetuximab in Recurrent/Metastatic SCCHN
NCT04590963Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- May 2022
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Monalizumab + Cetuximab with Placebo + Cetuximab (2 arms). Primary endpoint: Overall Survival at 17.5 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
monalizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04590963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590963.